136 related articles for article (PubMed ID: 7696962)
61. Sargramostim (rhu GM-CSF) as Cancer Therapy (Systematic Review) and An Immunomodulator. A Drug Before Its Time?
Lazarus HM; Ragsdale CE; Gale RP; Lyman GH
Front Immunol; 2021; 12():706186. PubMed ID: 34484202
[TBL] [Abstract][Full Text] [Related]
62. Effects of granulocyte-macrophage colony-stimulating factor on wound contraction.
Robson M; Kucukcelebi A; Carp SS; Hayward PG; Hui PS; Cowan WT; Ko F; Cooper DM
Eur J Clin Microbiol Infect Dis; 1994; 13 Suppl 2():S41-6. PubMed ID: 7875152
[TBL] [Abstract][Full Text] [Related]
63. A new concept in the treatment of extravasation injury: controlled drug delivery systems.
Konas E; Canter HI; Korkusuz P; Demir D; Oner F; Mavili ME
J BUON; 2010; 15(3):592-600. PubMed ID: 20941833
[TBL] [Abstract][Full Text] [Related]
64. The biology and clinical applications of granulocyte-macrophage colony-stimulating factor.
Sakamoto KM; Golde DW; Gasson JC
J Pediatr; 1991 Mar; 118(3):S17-20. PubMed ID: 1999769
[TBL] [Abstract][Full Text] [Related]
65. Clinical uses of GM-CSF, a critical appraisal and update.
Arellano M; Lonial S
Biologics; 2008 Mar; 2(1):13-27. PubMed ID: 19707424
[TBL] [Abstract][Full Text] [Related]
66. Vaccine adjuvancy: a new potential area of development for GM-CSF.
Taglietti M
Adv Exp Med Biol; 1995; 378():565-9. PubMed ID: 8526143
[No Abstract] [Full Text] [Related]
67. GM-CSF as adjuvant for immunotherapy with bispecific antibodies.
Elsässer D; Stadick H; van de Winkel JG; Valerius T
Eur J Cancer; 1999 Aug; 35 Suppl 3():S25-8. PubMed ID: 10645218
[No Abstract] [Full Text] [Related]
68. Immunomodulation: the role of hematopoietic cytokines.
Lonial S
Support Cancer Ther; 2004 Jan; 1(2):80-8. PubMed ID: 18628184
[TBL] [Abstract][Full Text] [Related]
69. Local injections of granulocyte-macrophage colony-stimulating factor (Gm-CSF) for the treatment of radiation-induced mucosa ulcers.
Raoul JL; Cadre B; Le Prisé E; Boucher E
Radiother Oncol; 2003 Sep; 68(3):303-4. PubMed ID: 13129640
[TBL] [Abstract][Full Text] [Related]
70. GM-CSF and wound healing.
Wheeler G; Brodie GN
Med J Aust; 1998 Jun; 168(11):580. PubMed ID: 9640310
[No Abstract] [Full Text] [Related]
71. Wound Healing: Experience With rHuGM-CSF.
Castrogiovanni P; Ventimiglia P; Imbesi R
Wounds; 2010 Oct; 22(10):256-60. PubMed ID: 25901492
[TBL] [Abstract][Full Text] [Related]
72. A comparison of cancer vaccine adjuvants in clinical trials.
Marriott M; Post B; Chablani L
Cancer Treat Res Commun; 2023; 34():100667. PubMed ID: 36516613
[TBL] [Abstract][Full Text] [Related]
73. Successful use of a defined antigen/GM-CSF adjuvant vaccine to treat mucosal Leishmaniasis refractory to antimony: A case report.
Badaro R; Lobo I; Nakatani M; Muiños A; Netto EM; Coler RN; Reed SG
Braz J Infect Dis; 2001 Aug; 5(4):223-32. PubMed ID: 11712967
[TBL] [Abstract][Full Text] [Related]
74. GM-CSF in the treatment of skin ulceration in breast cancer.
Wandl UB
J Wound Care; 1997 Apr; 6(4):165-6. PubMed ID: 9256714
[No Abstract] [Full Text] [Related]
75. Accelerating skin wound healing by M-CSF through generating SSEA-1 and -3 stem cells in the injured sites.
Li Y; Jalili RB; Ghahary A
Sci Rep; 2016 Jul; 6():28979. PubMed ID: 27363517
[TBL] [Abstract][Full Text] [Related]
76. Advances in the understanding and treatment of sepsis-induced immunosuppression.
Venet F; Monneret G
Nat Rev Nephrol; 2018 Feb; 14(2):121-137. PubMed ID: 29225343
[TBL] [Abstract][Full Text] [Related]
77. Topical granulocyte-macrophage colony-stimulating factor in patients with cancer and impaired wound healing.
Raderer M; Kornek G; Hejna M; Koperna K; Scheithauer W; Base W
J Natl Cancer Inst; 1997 Feb; 89(3):263. PubMed ID: 9017010
[No Abstract] [Full Text] [Related]
78. Digital necroses and Sharp's syndrome: the success of topical application of granulocyte/macrophage-colony stimulating factor in promoting healing after amputation of three toes.
Gaches F; Blanc AS; Couret B; Arlet-Suau E
Br J Dermatol; 1998 Mar; 138(3):550-1. PubMed ID: 9580824
[No Abstract] [Full Text] [Related]
79. Immunomodulators. Future prospects.
Takx-Köhlen BC
Pharm Weekbl Sci; 1992 Aug; 14(4A):245-52. PubMed ID: 1437506
[TBL] [Abstract][Full Text] [Related]
80. Antimicrobial immunotherapeutics: past, present and future.
Mercer DK; Francis ML; Fraser-Pitt D
Emerg Top Life Sci; 2021 Nov; 5(5):609-628. PubMed ID: 34196722
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
